Microchip-based OCT Measures Retinal Tissue can become noninvasive, highly accurate, Alzheimer's biomarker 10-15 years ahead of symptom onset
Research at Columbia University has developed a microchip tool that can produce accurate 3D images of retinal tissue that can be analyzed to show the earliest symptoms of Alzheimer's disease. This test can provide clinicians and their patients with 10-15 years lead time to make changes in lifestyle and other factors to reduce the chances of developing dementia symptoms.
Quietmind Fdn's research studies and supports the development of noninvasive techniques and is working with experts in OCT to create a comprehensive risk assessment suite that can be easily deployed worldwide to evaluate and treat the underlying causes of neurodegeneration.
For more information about our ongoing non-drug noninvasive clinical trials at Quietmind Foundation click https://www.quietmindfdn.org/trials.html: or call 610-940-0488
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.